Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PPD Strengthens Oncology Expertise for Drug Development | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

PPD Strengthens Oncology Expertise for Drug Development

Panteli Theocharous named vice president of global product development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharmaceutical Product Development (PPD) has appointed Panteli Theocharous vice president of global product development in the hematology/oncology therapeutic area.

“Panteli brings extensive expertise in hematology and oncology and biopharmaceutical R&D to PPD’s global product development team,” said Rob Dow, senior vice president of medical affairs, PPD. “Panteli is a recognized thought leader in oncology, and throughout his career he has worked on marketing authorization applications, lifecycle management and pricing and reimbursement negotiations for more than 20 hematology and oncology molecules.”

Hematology and oncology form one of PPD’s leading therapeutic areas, with more than 400 studies with clinical components conducted in this area in the past five years.

Mr. Theocharous most recently served as vice president and head of clinical and medical affairs at Cell Therapeutics, Life Sciences in London. Previously, he was with Johnson & Johnson, where he held leadership positions in global medical affairs, clinical development and regulatory affairs for the company’s hematology/oncology research and development programs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics